Y Career Fellowship (1090462); Q.Q.H., Melbourne Study Scholarship; H.H.T., NHMRC Postgraduate Scholarship; N.F.G. and C.W., Wellcome Trust (WT107881); C.W., Healthcare Integrin alpha V beta 8 Proteins Synonyms Investigation Council (MC_UU_00002/4); J.K., Sigrid Juselius Foundation, Academy of Finland (297338 and 307247) and Novo Nordisk Foundation (NNF17OC0026062); P.W., Novo Nordisk Foundation (15998) and Academy of Finland (312476 and 312477); T.L., Academy of Finland (322098); A.S.H., Academy of Finland (321356); and V.S., Finnish Foundation for Cardiovascular Analysis.Declaration of InterestsVeikko Salomaa has consulted for Novo Nordisk and Death Receptor 4 Proteins Molecular Weight Sanofi and received honoraria from these businesses. He also has ongoing analysis collaboration with Bayer Ltd. (All unrelated towards the present study). The other authors declare no conflicts of interest. Received: May possibly 14, 2019 Accepted: September 30, 2019 Published: October 31,Internet ResourcesBLUEPRINT immune cell summary statistics, ftp://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/ eQTLGen Consortium portal, http://www.eqtlgen.org/ GWAS Catalog, https://www.ebi.ac.uk/gwas/ ImmunoBase, https://www.immunobase.org/ LD Hub, http://ldsc.broadinstitute.org/ldhub/ OMIM, https://www.omim.org/ PLINK, https://www.cog-genomics.org/plink2 Summary statistics in the multivariate GWAS meta-analyses, https://www.ebi.ac.uk/gwas/downloads/summary-statistics
Toxins 2013, five, 336-362; doi:10.3390/toxinsOPEN ACCESStoxinsISSN 2072-6651 www.mdpi.com/journal/toxins ReviewThe Doable Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine–The Knowledge in Acute Myeloid Leukemia from Illness Improvement and Diagnosis through Standard Chemotherapy to Allogeneic Stem Cell TransplantationH on Reikvam 1,two, Hanne Fredly 1,2, Astrid Olsnes Kittang two and stein Bruserud 1,two,Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen N-5021, Norway; E-Mails: [email protected] (H.R.); [email protected] (H.F.) Institute of Medicine, University of Bergen, Bergen N-5021, Norway; E-Mail: [email protected] Author to whom correspondence ought to be addressed; E-Mail: [email protected]; Tel.: +47-5597-5000; Fax: +47-5597-2950. Received: 17 January 2013; in revised kind: 5 February 2013 / Accepted: 6 February 2013 / Published: 18 FebruaryAbstract: Chemokines are critical regulators of numerous diverse biological processes, such as (i) inflammation with activation and nearby recruitment of immunocompetent cells; (ii) angiogenesis as a a part of inflammation or carcinogenesis; and (iii) as a bridge amongst the coagulation program and inflammation/immune activation. The systemic levels of a variety of chemokines may perhaps thus reflect nearby illness processes, and such variations may thereby be utilized in the routine clinical handling of individuals. The expertise from sufferers with myeloproliferative diseases, and particularly individuals with acute myeloid leukemia (AML), suggests that systemic plasma/serum cytokine profiles might be helpful, both as a diagnostic tool and for prognostication of individuals. On the other hand, cytokines/chemokines are released by a wide range of cells and are involved inside a wide selection of biological processes; the altered levels may thus mostly reflect the strength and nature of your biological processes, plus the optimal clinical use of chemokine/cytokine analyses may thus demand mixture with organ-specific biomarkers. Chemokine levels are also altered by clinical procedures, therapeut.